200 related articles for article (PubMed ID: 32632237)
1. Comparative safety and effectiveness of alendronate versus raloxifene in women with osteoporosis.
Kim Y; Tian Y; Yang J; Huser V; Jin P; Lambert CG; Park H; You SC; Park RW; Rijnbeek PR; Van Zandt M; Reich C; Vashisht R; Wu Y; Duke J; Hripcsak G; Madigan D; Shah NH; Ryan PB; Schuemie MJ; Suchard MA
Sci Rep; 2020 Jul; 10(1):11115. PubMed ID: 32632237
[TBL] [Abstract][Full Text] [Related]
2. Incidence and risk of osteonecrosis of the jaw among the Taiwan osteoporosis population.
Lin TC; Yang CY; Kao Yang YH; Lin SJ
Osteoporos Int; 2014 May; 25(5):1503-11. PubMed ID: 24515577
[TBL] [Abstract][Full Text] [Related]
3. Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture.
Cadarette SM; Katz JN; Brookhart MA; Stürmer T; Stedman MR; Solomon DH
Ann Intern Med; 2008 May; 148(9):637-46. PubMed ID: 18458276
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of osteoporosis drugs in preventing secondary nonvertebral fractures in Taiwanese women.
Lin TC; Yang CY; Yang YH; Lin SJ
J Clin Endocrinol Metab; 2013 Dec; 98(12):4717-26. PubMed ID: 24081731
[TBL] [Abstract][Full Text] [Related]
5. Real-world evidence of raloxifene versus alendronate in preventing non-vertebral fractures in Japanese women with osteoporosis: retrospective analysis of a hospital claims database.
Tanaka S; Yamamoto T; Oda E; Nakamura M; Fujiwara S
J Bone Miner Metab; 2018 Jan; 36(1):87-94. PubMed ID: 28028633
[TBL] [Abstract][Full Text] [Related]
6. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
7. Incidence and risk of venous thromboembolism among Taiwan osteoporotic fracture population under osteoporosis pharmacological treatments.
Lin TC; Lee CH; Yang CY; Yang YH; Lin SJ
J Clin Endocrinol Metab; 2014 May; 99(5):1599-607. PubMed ID: 24606074
[TBL] [Abstract][Full Text] [Related]
8. Fractures in women treated with raloxifene or alendronate: a retrospective database analysis.
Foster SA; Shi N; Curkendall S; Stock J; Chu BC; Burge R; Diakun DR; Krege JH
BMC Womens Health; 2013 Mar; 13():15. PubMed ID: 23521803
[TBL] [Abstract][Full Text] [Related]
9. The influence of alendronate and tooth extraction on the incidence of osteonecrosis of the jaw among osteoporotic subjects.
Chiu WY; Yang WS; Chien JY; Lee JJ; Tsai KS
PLoS One; 2018; 13(4):e0196419. PubMed ID: 29694412
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review.
Fink HA; MacDonald R; Forte ML; Rosebush CE; Ensrud KE; Schousboe JT; Nelson VA; Ullman K; Butler M; Olson CM; Taylor BC; Brasure M; Wilt TJ
Ann Intern Med; 2019 Jul; 171(1):37-50. PubMed ID: 31009947
[TBL] [Abstract][Full Text] [Related]
11. Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass.
Recker RR; Kendler D; Recknor CP; Rooney TW; Lewiecki EM; Utian WH; Cauley JA; Lorraine J; Qu Y; Kulkarni PM; Gaich CL; Wong M; Plouffe L; Stock JL
Bone; 2007 Apr; 40(4):843-51. PubMed ID: 17182297
[TBL] [Abstract][Full Text] [Related]
12. Hip and subtrochanteric or diaphyseal femoral fractures in alendronate users: a 10-year, nationwide retrospective cohort study in Taiwanese women.
Hsiao FY; Huang WF; Chen YM; Wen YW; Kao YH; Chen LK; Tsai YW
Clin Ther; 2011 Nov; 33(11):1659-67. PubMed ID: 22018450
[TBL] [Abstract][Full Text] [Related]
13. Alendronate and raloxifene use related to cardiovascular diseases: differentiation by different dosing regimens of alendronate.
Lu PY; Hsieh CF; Tsai YW; Huang WF
Clin Ther; 2011 Sep; 33(9):1173-9. PubMed ID: 21849210
[TBL] [Abstract][Full Text] [Related]
14. Adherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors.
Cadarette SM; Solomon DH; Katz JN; Patrick AR; Brookhart MA
Osteoporos Int; 2011 Mar; 22(3):943-54. PubMed ID: 20532481
[TBL] [Abstract][Full Text] [Related]
15. The risk of osteonecrosis of the jaws in Taiwanese osteoporotic patients treated with oral alendronate or raloxifene.
Chiu WY; Chien JY; Yang WS; Juang JM; Lee JJ; Tsai KS
J Clin Endocrinol Metab; 2014 Aug; 99(8):2729-35. PubMed ID: 24758181
[TBL] [Abstract][Full Text] [Related]
16. Randomized head-to-head comparison of minodronic acid and raloxifene for fracture incidence in postmenopausal Japanese women: the Japanese Osteoporosis Intervention Trial (JOINT)-04.
Uemura Y; Sone T; Tanaka S; Miyazaki T; Tsukiyama M; Taguchi A; Soen S; Mori S; Hagino H; Sugimoto T; Fukunaga M; Ohta H; Nakamura T; Orimo H; Shiraki M;
Curr Med Res Opin; 2020 Nov; 36(11):1847-1859. PubMed ID: 32870712
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Iwamoto J; Takeda T; Sato Y
Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
[TBL] [Abstract][Full Text] [Related]
18. Systematic review of raloxifene in postmenopausal Japanese women with osteoporosis or low bone mass (osteopenia).
Fujiwara S; Hamaya E; Sato M; Graham-Clarke P; Flynn JA; Burge R
Clin Interv Aging; 2014; 9():1879-93. PubMed ID: 25395843
[TBL] [Abstract][Full Text] [Related]
19. Effect of alendronate for reducing fracture by FRAX score and femoral neck bone mineral density: the Fracture Intervention Trial.
Donaldson MG; Palermo L; Ensrud KE; Hochberg MC; Schousboe JT; Cummings SR
J Bone Miner Res; 2012 Aug; 27(8):1804-10. PubMed ID: 22492479
[TBL] [Abstract][Full Text] [Related]
20. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
Saag KG; Petersen J; Brandi ML; Karaplis AC; Lorentzon M; Thomas T; Maddox J; Fan M; Meisner PD; Grauer A
N Engl J Med; 2017 Oct; 377(15):1417-1427. PubMed ID: 28892457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
